Delving into the Latest Updates on Tacalcitol Hydrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Bonalfa, Psoraderm, Psoravit

+ [13]

Target

VDR

Mechanism

VDR agonists(Vitamin D receptor agonists)

Therapeutic Areas

Immune System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases+ [1]

Active Indication

Psoriasis vulgarisIchthyosisPityriasis+ [2]

Inactive Indication-

Originator Organization-

Active Organization

Iwaki Seiyaku Co., Ltd.Teijin Pharma Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

(01 Jan 1993),

Psoriasis

Regulation-

Login to view timeline

Structure

Molecular FormulaC27H46O4

InChIKeyUCLYOJXQGOXQKJ-XXBHHXRKSA-N

CAS Registry93129-94-3

View All Structures (2)

This study will compare efficacy and safety of once daily treatment of calcipotriol plus betamethasone dipropionate gel (LEO 80185) with tacalcitol ointment and LEO 80185 vehicle alone in subjects with psoriasis vulgaris. Subjects will be treated for up to 8 weeks followed by an observation period of up to 8 weeks to investigate the occurence and the time to relapse and occurence of rebound after discontinuation of the investigational products. Only subjects with "controlled disease" will be considered for this observation phase of the study. "Controlled disease" is defined as "Clear" or "Almost Clear" severity category based on Investigator's global assessment (IGA).

Start Date01 Apr 2008

Sponsor / Collaborator

Leo Pharma, Inc.

EUCTR2006-001126-90-DE / Not yet recruitingNot Applicable

Evaluation of safety and efficacy of Curatoderm® Emulsion in the treatment of patients with mild to moderate plaque psoriasis - n.a.

Start Date06 Jul 2006

Sponsor / Collaborator

HERMAL Kurt Herrmann GmbH & Co. oHG

100 Clinical Results associated with Tacalcitol Hydrate

Login to view more data

100 Translational Medicine associated with Tacalcitol Hydrate

Login to view more data

100 Patents (Medical) associated with Tacalcitol Hydrate

Login to view more data

203

Literatures (Medical) associated with Tacalcitol Hydrate

31 Dec 2024·Journal of Dermatological Treatment

Comparison of various excimer laser (EL) combination therapies for vitiligo: a systematic review and network meta-analysis

Review

Author: Wang, XinYue ; Shi, Lei ; Mu, ZengYi ; Wang, YaPing ; Li, XinHong ; Hu, Yue ; Li, ChanXiu ; Sun, Xiao

AIMThis study aimed to compare the efficacy and safety of excimer laser (EL)-based combination regimens in improving repigmentation.METHODSA comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, and Embase on July 1, 2023, to include randomized controlled trials of EL combination treatments for vitiligo that met the criteria. The primary outcome measure was a repigmentation rate ≥ 75%, and the secondary outcome measures were a repigmentation rate of ≤ 25% and adverse events.RESULTSEleven studies involving 348 patients were included. Network Meta-Analysis showed that EL combined with antioxidants (SUCRA = 98.8%), EL combined with calcipotriol (SUCRA = 59.8%) and EL combined with tacalcitol (SUCRA = 59.6%) were the three optimal interventions achieving repigmentation rates ≥ 75%. EL alone (SUCRA = 77.6%), EL combined with tacalcitol (SUCRA = 61.7%) and EL combined with antioxidants (SUCRA = 57.2%) were the three interventions with the highest rates of treatment failure. Adverse events in all groups mainly included erythema, burning sensation and hyperpigmentation. Based on the results of the current study, EL combination therapies were safe with mild adverse events.CONCLUSIONEL combined with antioxidants was the preferred regimen for vitiligo, whereas EL alone was the regimen with the highest rate of treatment failure in vitiligo.

22 Nov 2023·Journal of Biomolecular Structure and Dynamics

Phytochemical investigation, structural elucidation, in silico study and anti-psoriatic activity of potent bioactive from Betula utilis

Article

Author: Ghosh, Goutam ; Biswasroy, Prativa ; Bhola, Rajesh Kumar ; Rath, Goutam ; Halder, Jitu ; Kar, Biswakanth ; Pradhan, Deepak ; Sahu, Dipak Kumar ; Rai, Vineet ; Rajwar, Tushar Kanti

Psoriasis is a chronic autoimmune pathological condition characterized by hyperactivation of proinflammatory cytokines (IL-6, TNF-α, IL-17, IL-23, etc.). Severe drug-associated toxicities like hepatotoxicity and nephrotoxicity (Methotrexate), teratogenicity (Tazarotene), hypercholesterolemia (Cyclosporine) and hypercalcemia (tacalcitol), are the forefront challenges that demand an alternative approach for the treatment of psoriasis. In the present study, a natural lead molecule 'Betulin' (BE, lup-20(29)-ene-3b,28-diol) was isolated from Betula utilis and subsequently, structure-based molecular docking was employed to identify the molecular target for psoriasis. The computational analysis reflects better affinity of BE towards pro-inflammatory cytokine as compared to standard drugs. Apart from this BE shows a greater affinity towards the overexpressed Glut-1 receptor in comparison to standard drug Metformin (Met). Based on the in silico screening the isolated lead compound was further processed for the evaluation of anti-psoriatic activity via imiquimod (IMQ 5%) induced psoriasis-like skin inflammation model. In vivo screening models were characterized by different parameters (psoriasis area and severity index (PASI) scores, macroscopically and behavioral evaluation, splenomegaly, cytokine levels and histological changes) and compared among the experimental groups. The experimental finding reflects comparable results of PASI score, i.e., 57.14% and 61.9% recovery of test BE-solution (180 mg/kg) and standard Betamethasone di-propionate ointment (BD-oint.0.5 mg/g), respectively. Focusing on other parameters, BE shows relative results such as an enhanced macroscopically with behavioral conditions, reducing the expression of proinflammatory cytokine as well as restoring histological changes with that of BD. These findings suggest that BE-isolated phytoconstituents from Betula utilis could be a potential agent and a step closer to psoriasis treatment. HIGHLIGHTPsoriasis is a multifaceted, immunologically mediated disease consequences production of high levels of proinflammatory mediators and overexpression of Glut-1 transporters that trigger keratinocyte proliferation and inflammatory cascades.A Himalayan silver birch, Betula utilis (Bhojpatra) contains many steroidal terpenes which are responsible for various pharmacological activities that could be exploited in drug development in psoriasis.The computational analysis of BE reflects a better affinity toward the proinflammatory cytokines with their target receptors and indicates a satisfactory range with a slight deviation from Jorgensen and Lipinski's rule and possesses a significant drug choice for psoriasis.Preclinical findings of BE-solution (BE-sol) give a positive response towards IMQ-induced psoriasis-like skin inflammation model.[Figure: see text]Communicated by Ramaswamy H. Sarma.

01 Jul 2023·Steroids

Investigation on the synthesis of 24-(R)-hydroxycholesterol

Article

Author: Zhao, Haiyun ; Zhong, Zhicheng ; Sun, Bin ; Jin, Can ; Chen, Maojie ; Wang, Jiayang

A facile and novel strategy has been developed for synthesis of 24-(R)-hydroxycholesterol, a key intermediate of tacalcitol, starting from 24-dehydrocholesterol in seven steps with 48.2% overall yield and high diastereomer ratio. Photocatalytic oxidation of olefins by employing inexpensive Rose Bengal as photosensitizer and air as the sole oxidant for the preparation of Δ^5,25-3β-Hydroxycholestadiene-24-one-3-acetate is the key step in this synthetic route. This developed strategy features mild conditions, satisfied total yield and excellent stereoselectivity (24-R/S = 97.7:2.3), providing a novel access to the 24-(R)-hydroxycholesterol.

100 Deals associated with Tacalcitol Hydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01472	Tacalcitol Hydrate	D05AX04	DB13689

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Psoriasis vulgaris	JP	Iwaki Seiyaku Co., Ltd.	05 Jul 2002
Ichthyosis	JP	Iwaki Seiyaku Co., Ltd.	01 Oct 1993
Pityriasis	JP	Iwaki Seiyaku Co., Ltd.	01 Oct 1993
Pustulosis of Palms and Soles	JP	Iwaki Seiyaku Co., Ltd.	01 Oct 1993
Psoriasis	-	-	01 Jan 1993